These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34734431)

  • 1. The efficacy and safety of immune checkpoint inhibitor in patients with relapsed small-cell lung cancer: A systematic review and meta-analysis.
    Xu Y; Chen M; Ding Y; Guo F; Chen M; Lu T
    J Clin Pharm Ther; 2022 Apr; 47(4):421-429. PubMed ID: 34734431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing strategy of immune checkpoint inhibitors plus chemotherapy with chemotherapy alone for small cell lung cancer: a meta-analysis based on six RCTs incorporating 2800 participants.
    Zhong Y; Wu Q; Wu S; Xie X
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2465-2474. PubMed ID: 34533625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
    Chen C; Tian P; Zhong J; Fan X
    Front Oncol; 2023; 13():1151769. PubMed ID: 37152041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
    Korde R; Veluswamy R; Allaire JC; Barnes G
    Curr Med Res Opin; 2022 Aug; 38(8):1361-1368. PubMed ID: 35575164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models.
    Zheng J; Deng Y; Huang B; Chen X
    Front Med (Lausanne); 2023; 10():1198950. PubMed ID: 37583422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
    Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC).
    Ma X; Wang S; Zhang Y; Wei H; Yu J
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):593-606. PubMed ID: 32852633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
    Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
    J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
    Qin Q; Wang J; Wang H
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of different immunotherapies combined with chemotherapy as first-line therapy in patients with small cell lung cancer: a network meta-analysis.
    Gong S; Li Q; Yu X; Yang S
    Front Immunol; 2024; 15():1362537. PubMed ID: 38694505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.
    Schmid S; Mauti LA; Friedlaender A; Blum V; Rothschild SI; Bouchaab H; Frösch P; Britschgi C; König D; Wannesson L; Janthur WD; Schär S; Demmer I; Addeo A; Jochum W; Früh M
    Cancer Immunol Immunother; 2020 Aug; 69(8):1605-1613. PubMed ID: 32307579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating Oral Probiotic Supplements as Complementary Treatment in Advanced Lung Cancer Patients Receiving ICIs: A Prospective Real-World Study.
    Tong L; Wan Y; Shi X; Liu X; Liu Z; Li Y; Zhang Y; Luo D; Zhu J
    Cancer Control; 2024; 31():10732748241253959. PubMed ID: 38736182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
    Front Immunol; 2021; 12():731546. PubMed ID: 34484242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer.
    Ying X; Shi Z; Shao R; You G; Song Z
    Neoplasma; 2024 Jun; 71(3):297-305. PubMed ID: 38958712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis.
    Zhang S; Bi M
    Ann Palliat Med; 2020 Nov; 9(6):4081-4088. PubMed ID: 33302668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
    Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
    Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.